Robert Smith
Direktor/Vorstandsmitglied bei CITIUS PHARMACEUTICALS, INC.
Profil
Robert J.
Smith is currently an Independent Director at Citius Pharmaceuticals, Inc. and the President at Bamboo Therapeutics, Inc. He has an MBA from the University of Rochester Simon Business School and an undergraduate degree from Rochester Christian University.
Aktive Positionen von Robert Smith
| Unternehmen | Position | Beginn |
|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 12.03.2024 |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Präsident | - |
Ausbildung von Robert Smith
| Rochester Christian University | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
